We applied a combined proteomic and metabolomic approach to obtain novel mechanistic insights in PKCɛ-mediated cardioprotection. Mitochondrial and cytosolic proteins from control and transgenic hearts with constitutively active or dominant negative PKCɛ were analyzed using difference in-gel electrophoresis (DIGE). Among the differentially expressed proteins were creatine kinase, pyruvate kinase, lactate dehydrogenase, and the cytosolic isoforms of aspartate amino transferase and malate dehydrogenase, the two enzymatic components of the malate aspartate shuttle, which are required for the import of reducing equivalents from glycolysis across the inner mitochondrial membrane. These enzymatic changes appeared to be dependent on PKCɛ activity, as they were not observed in mice expressing inactive PKCɛ. High-resolution proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy confirmed a pronounced effect of PKCɛ activity on cardiac glucose and energy metabolism: normoxic hearts with constitutively active PKCɛ had significantly lower concentrations of glucose, lactate, glutamine and creatine, but higher levels of choline, glutamate and total adenosine nucleotides. Moreover, the depletion of cardiac energy metabolites was slower during ischemia/reperfusion injury and glucose metabolism recovered faster upon reperfusion in transgenic hearts with active PKCɛ. Notably, inhibition of PKCɛ resulted in compensatory phosphorylation and mitochondrial translocation of PKCδ. Taken together, our findings are the first evidence that PKCɛ activity modulates cardiac glucose metabolism and provide a possible explanation for the synergistic effect of PKCδ and PKCɛ in cardioprotection.
Introduction
Protein kinase C (PKC) is a heterogeneous family of phospholipiddependent kinases. Notably, the PKCɛ and the PKCδ isoforms have both been implicated in cardioprotection as translocation of activated PKCɛ and PKCδ to the membrane fraction has been detected in preconditioned hearts [1] . PKCɛ activation and PKCδ inhibition are thought to be involved in myocardial salvage and combined treatment with PKCδ inhibitor and PKCɛ activator peptides exerted an additive protective effect on the ischemic heart [2] [3] [4] [5] [6] [7] . On the other hand, expression of active PKCδ increased resistance to simulated ischemia in neonatal cardiomyocytes [8] . Thus, although it is now widely accepted that PKC isoforms play a pivotal role in mediating both the early and the late phase of ischemic preconditioning [9] [10] [11] , the mechanisms responsible for PKC-mediated ischaemic preconditioning are still debated. While numerous studies have addressed potential targets of PKC in cardiac signalling [12] [13] [14] [15] , the role of these specific PKC isoforms in cardiac metabolism is less clear.
To further advance our understanding of how PKC isoforms alter cardiac metabolism, we have previously identified protein and metabolite changes after ischemic preconditioning [16] and demonstrated that loss of PKCδ altered glucose metabolism resulting in a reduction in the ratio of cardiac glucose to lipid metabolites [17] . We now integrate protein with metabolite changes in cardioprotected mice with transgenic activation of PKCɛ and unravel metabolic changes occurring during ischemia/reperfusion injury. Our data are the first evidence that the cardioprotective effect of PKCɛ activation on mitochondrial function may be, in part, an indirect effect of modulating cardiac glucose metabolism providing an explanation for the synergistic effects of PKCɛ and PKCδ in cardioprotection.
Transgenic mice
Animals used in the present study were PKCɛ transgenic mice (ICR background) generated using a cDNA of active PKCɛ driven by the α-myosin heavy chain promoter to achieve cardiac-specific expression [12, 18] . AE PKCɛ transgenic mice express a PKCɛ molecule that favors the open and active conformation (A to E mutation at A159), whereas DN PKCɛ mice express a dominant negative form of the same molecule (A to E mutation at A159 and K to R mutation at K436). The hearts of AE PKCɛ mice exhibit a 6-fold overexpression of PKCɛ and an inherent resistance to infarction (as compared to wild type, ICR controls) that is not observed in the DN PKCɛ mice [12] . Transgenic and control mice were sacrificed at the age of 6 months. Only male animals were used in all the experiments. Hearts from 8-week-old PKCδ-deficient mice served as controls for validating the antibody specificity [19] .
Subcellular fractionation
Isolation of mitochondria was performed in the cold room at 4°C. Freshly-harvested mouse hearts were minced in 250 mM sucrose, 1 mM EGTA, 20 mM Hepes, pH 7.5 with a glass homogenizer. Nuclei and unbroken cells were pelleted by centrifugation at 1000 g for 10 min. The crude mitochondrial and cytosolic fraction was obtained from the supernatant by centrifugation at 4000 g for 30 min. The membrane fraction was obtained by centrifugation of the cytosolic fraction at 100,000 g for 1 h.
Proteomics
Key techniques involved adaptations of previously published protocols, including those for difference in-gel electrophoresis (DIGE) [20] , and nano-liquid chromatography tandem mass spectrometry (nano-LC MS/MS) [21] . Methods are described online. A detailed methodology is also available on our website http://www. vascular-proteomics.com. For proteomic analysis, mitochondrial and cytosolic protein extracts were prepared from 16 murine hearts (n = 6 for control and AE mice, n = 4 for DN mice). Two samples were pooled for each gel to obtain sufficient material for proteomic analysis. Differences in protein expression were analyzed using the Decyder software (Version 6.5, GE healthcare).
Murine model of regional myocardial ischemic injury
Myocardial infarction was induced in the anesthetized mouse using an established protocol of regional ischemic injury [22] . Briefly, male ICR mice were subjected to a 30 min left anterior descending coronary artery occlusion followed by 30 min of reperfusion. Sham control group was subjected to open chest surgery without coronary occlusion.
Metabolomics
For metabolomic analysis, metabolite extracts were prepared from 29 murine hearts (n = 5 for normoxic control and AE PKCɛ mice, n = 4 for control and n = 3 for AE PKCɛ mice after ischemia, and n = 4 for control, AE and DN PKCɛ mice after 30 min reperfusion, respectively). Water-soluble metabolites were extracted in 6% perchloric acid and proton magnetic resonance spectroscopy ( 1 H-NMR) was performed as described online [23] .
Statistical analysis
Statistical analysis was performed using the analysis of variance (ANOVA) and unpaired Student's t-test. Pairwise comparisons between metabolites were performed using the Bonferroni/Dunn Fig. 1 . Subcellular fractionation. Mitochondrial and cytosolic extracts were prepared from murine hearts as described in the Methods section. The purity of the fractions was assessed by Western blotting for VDAC, a mitochondrial outer membrane protein, and myoglobin, an abundant cytosolic protein (A). Panel B illustrates the depletion of nuclear proteins (NuMA) and the enrichment of mitochondrial (prohibitin) compared to other membrane proteins (Na + /K + ATPase).
test. Results were given as means ± SE. A P value b0.05 was considered significant. Principal component analysis (PCA) was used for the analysis of the multivariate data produced by proteomic and metabolomic technologies, which reduces the data dimensionality. For proteomic datasets, DIGE gels were analyzed using the extended data analysis (EDA) module of the Decyder software (GE healthcare). For metabolite profiles, the 1 H-NMR spectra were used for generating bucket tables for PCA analysis.
Results

The proteome of PKCɛ transgenic hearts
To provide insights into potential cellular targets of PKCɛ, we compared the mitochondrial and cytosolic proteome of control hearts and transgenic hearts with constitutively active (AE) and dominant negative (DN) PKCɛ by DIGE. The quality of subcellular fractionation was assessed by immunoblotting ( Fig. 1) . The intactness of mitochondria was verified by the calcium swelling assay as described [24] . A representative image of the cardiac mitochondrial and cytosolic fraction as separated by two-dimensional gel electrophoresis (2-DE, pH 3-10 nonlinear) is presented in Fig. 2 . Differentially expressed spots are numbered and protein identifications as obtained by nano-LC MS/MS analysis are listed in online Tables I-III . Only a few mitochondrial proteins in AE transgenic hearts were consistently different from control as well as DN transgenic hearts, including mitofilin (Supplemental Fig. 1A ), an inner mitochondrial membrane protein and regulator of metabolic flux, and manganese superoxide dismutase, an important mitochondrial antioxidant (Supplemental Table I ). The latter was subsequently confirmed by immunoblotting (Supplemental Fig. 2) . No difference in net expression was observed for mitofillin because post-translational modifications as well as changes in net expression can be visualized on 2-DE gels (Supplemental Fig. 1A ).
Besides mitochondria, several cytosolic enzymes related to glucose and energy metabolism were profoundly influenced by PKCɛ activation (Supplemental Table III , Supplemental Fig. 1B ), including pyruvate kinase, enolase, lactate dehydrogenase, creatine kinase, as well as cytosolic malate dehydrogenase and cytosolic aspartate aminotransferase. The latter two enzymes constitute the components of the malate-aspartate shuttle, which exchanges cytoplasmic malate for mitochondrial aspartate and allows the transport of glycolyticallyderived reducing equivalents across the inner mitochondrial membrane. When cross-validation was performed using principal component analysis (PCA) to investigate the global variation in the proteomic space, the differentially expressed cytosolic proteins allowed a clear separation of control and transgenic hearts (Figs. 3A-C).
Unexpectedly, the proteomic experiments also revealed a pronounced effect of PKCɛ inhibition on the mitochondrial pyruvate dehydrogenase complex (Supplemental Table II ). The latter consists of E1 [the pyruvate dehydrogenase (decarboxylating) (alpha)2/(beta)2 heterotetramer], E2 (the dihydrolipoamide acetyltransferase) and E3 (the dihydrolipoyl dehydrogenase). Component X is an E3-binding protein and/or an E2 ancillary subunit with E2-like activity. Given that a 1:1 stoichiometry should exist between E1-alpha and E1-beta, the opposing directionality in changes observed in the proteomic experiment, suggests a post-translational modification. This was further substantiated by our finding that pyruvate dehydrogenase kinase 4, an inducible regulatory component, was identified within the protein spot containing E1-alpha. Phosphorylation of E1 by pyruvate dehydrogenase kinase (PDK) inactivates E1 and subsequently the entire pyruvate dehydrogenase complex. No statistically significant Fig. 2 . 2-DE map of cardiac proteins in the mitochondrial and cytosolic fraction. Subcellular protein extracts were pre-labelled with Cy3 and Cy5 using the DIGE approach and coseparated on large format 2-DE gels using pH 3-10NL IPG strips followed by 12% SDS polyacrylamide gels. Images were acquired on a fluorescence scanner and counterstained with silver. A silver-stained image of mitochondrial extracts and a DIGE image of cytosolic extracts is shown in panels A and B, respectively. Analyses using DeCyder ® software revealed the spots showing a significant difference in AE or DN hearts. Proteins were numbered and identified by nano-LC MS/MS (Supplemental Table I-III). differences were found for cytosolic proteins. When the differentially expressed proteins were submitted to Ingenuity Pathway Analysis (Ingenuity System, Mountain View, CA), the computational algorithms built two dominant protein association networks (Supplemental Fig. 3 ) and returned pyruvate metabolism as the top canonical pathway. Thus, our proteomic data provide strong evidence for a previously unrecognized effect of PKCɛ activity on cardiac glucose metabolism.
Metabolomic analysis of normoxic PKCɛ transgenic hearts
To prove the functional relevance of the described enzymatic changes, we applied high-resolution is plotted in the bottom panel of Fig. 4 . The fact that the difference between the 2 means and the direction of largest variance (PC1) is so small suggests that the two groups are well separated, which is confirmed by the cross-validated classification. Metabolites responsible for the discrimination between the two groups have been assigned. The quantitative data are included as online Table IV . Levels of lactate, glucose, glutamine, leucine, taurine and total creatine were significantly lower in cardioprotected AE PKCɛ transgenic hearts, while choline, glutamate and adenosine nucleotides were higher compared to controls (Fig. 5A ).
Metabolomic analysis after ischemia/reperfusion injury
To trace metabolite changes during ischemia/reperfusion injury, we measured cardiac metabolites after 30 min of ischemia and 30 min reperfusion. Strikingly, no significant metabolite changes were detected between control and AE PKCɛ transgenic hearts immediately after ischemia (Supplemental Table V ), but differences reappeared upon reperfusion (Supplemental Table VI, Supplemental Fig. 4B ): After only 30 min of reperfusion, the adenosine nucleotide pool was again significantly higher in AE PKCɛ transgenic hearts. Similarly, the decline of the total creatine pool during ischemia/reperfusion injury was less pronounced. This maintenance of cardiac energy metabolites in AE PKCɛ transgenic hearts coincided with a faster recovery of glucose metabolites (Fig. 5B) . A direct comparison of average metabolite concentrations in control, AE and DN PKCɛ transgenic hearts provides further evidence that the activity of PKCɛ correlates with metabolic recovery upon reperfusion (Fig. 6 ).
Mitochondrial translocation of PKCδ in PKCɛ transgenic hearts
While cardiac glucose metabolism was clearly affected by PKCɛ activity, it remained to be determined whether there was a cross-talk between the PKCɛ and the PKCδ isoform [25] . Fig. 7 provides evidence that activation of PKCɛ did not lead to a compensatory change in PKCδ expression. Inhibition of PKCɛ, however, markedly increased phosphorylation of PKCδ at Thr 505 and promoted translocation of PKCδ to the cardiac mitochondria (Fig. 7A) . The specificity of the antibodies was confirmed by using PKCδ-deficient hearts (Figs. 7B, C) . These results provide additional support for the differential expression of the pyruvate dehydrogenase complex in DN PKCɛ hearts (Supplemental Table II) , as PKCδ Thr 505 phosphorylation is known to alter substrate specificity [26] and the pyruvate dehydrogenase complex is one of the likely targets of PKCδ on cardiac mitochondria [16, 17, 27] . Thus, the activation state of PKCɛ influences PKCδ and the pyruvate dehydrogenase complex, the key enzyme linking glycolysis to mitochondrial respiration.
Discussion
In previous studies, our laboratory has shown that transgenic activation of PKCɛ in the heart is sufficient to significantly reduce myocardial infarction after coronary artery occlusion [12, 28] . In the present study, we used a novel combination of gel-based proteomics and high-resolution 1 H-NMR spectroscopy-based metabolomics [29] , to investigate mechanisms of PKCɛ-mediated cardioprotection. This comprehensive analysis revealed that PKCɛ activation has a previously unrecognized effect on cardiac glucose metabolism [30, 31] .
PKCɛ and cardiac metabolism
Despite abundant information on PKCɛ signalling networks in the heart [12] [13] [14] 32] , the manner in which the actions of these various signalling molecules integrate into cardiac metabolism is still not well understood. To our knowledge, only two papers have previously addressed the effects of PKCɛ activation on cardiac metabolism: Cross et al [33] used 31 P-NMR spectroscopy to measure phosphorus metabolites during ischemia reperfusion injury in Langendorffperfused hearts. Despite maintaining a greater level of myocardial ATP during ischemia and reperfusion, the phosphocreatine content in AE PKCɛ transgenic hearts was similar to controls. McCarthy [34] et al. subsequently evaluated this phenotype in isolated mitochondria: they described a modest basal hyperpolarization in mitochondria from AE PKCɛ transgenic hearts versus controls. While no difference was observed in basal mitochondrial respiratory function by measuring oxygen consumption, respiratory-control index, and the rate of ATP production, PKCɛ activation augmented mitochondrial respiratory capacity in response to anoxia-reoxygenation. However, many issues of metabolism in AE PKCɛ hearts remain unresolved, especially with respect to the hearts in vivo.
Proteomics and metabolomics combined
Previous proteomic analyses of cardiac PKCɛ signalling complexes revealed metabolic enzymes as potential interacting partners of this serine/threonine kinase [13, 32] . We now demonstrate that some of the previously identified PKCɛ targets, i.e. creatine kinase, enolase, and the mitochondrial malate carrier, are indeed among the differentially expressed proteins in AE PKCɛ transgenic hearts. Moreover, as no data were available on how these interactions between PKCɛ and metabolic enzymes influence cardiac metabolism, we quantified cardiac metabolites in control and transgenic hearts under normoxia, after ischemia and after reperfusion injury. Our 1 H-NMR data on extracted cardiac metabolites not only confirmed the 31 P-NMR data on Langendorff-perfused hearts [33] in that cardiac energy metabolites were better preserved in AE PKCɛ transgenic hearts, but also provide a mechanistic underpinning for the observed cardioprotective phenotype: activation of PKCɛ resulted in lower lactate levels and a similar downregulation of cytosolic malate dehydrogenase isoforms as previously observed in preconditioned wildtype hearts [16] . Thus, PKCɛ activation induces proteomic and metabolic characteristics of a preconditioned cardiac phenotype, which were previously found to be abolished in hearts with targeted disruption of the PKCδ gene [16] .
Cross-talk between PKCɛ and PKCδ
The striking consistency between different genetically engineered mouse models suggests that the metabolic effects of PKCɛ may, at least partially, be interrelated with PKCδ. Subsequent experiments PKCɛ. pT denotes phosphothreonine (A). Verification of the antibody specificity by using hearts from PKCδ-deficient mice (B, C). The antibody for PKCδ-pThr 505 showed good specificity. The antibody for total PKCδ recognizes three bands, of which the middle one is specific for PKCδ.
confirmed a pronounced effect of PKCɛ activity on PKCδ translocation to cardiac mitochondria. Previously, increased expression and activation of PKCδ was observed in PKCɛ−/− mice [35, 36] . However, increased PKCδ activity in the complete absence of PKCɛ did not result in mitochondrial translocation of the PKCδ isoform. In our study, cardiac-specific manipulation of PKCɛ activity did not alter PKCδ expression, but inhibition of PKCɛ was associated with increased PKCδ loop phosphorylation, mitochondrial translocation and differential expression of the pyruvate dehydrogenase complex. These data confirm our previous results in PKCδ-deficient mice, where altered activity of the pyruvate dehydrogenase complex was postulated to be a likely explanation for the observed metabolic effects after deletion of the PKCδ gene [16, 17, 37] . Notably, despite increased PKCδ on mitochondria, transgenic hearts with DN PKCɛ showed no cardioprotective phenotype, which may be consistent with previous reports claiming that translocation of PKCδ is required for mediating cardioprotection after pharmacological [38] , but not ischemic preconditioning [39] . On the other hand, a moderate increase in mitochondrial PKCδ was also observed in AE PKCɛ hearts and similar to mice deficient for PKCɛ [35] , PKCδ knockout mice lost cardioprotection in response to ischemic preconditioning [16] . In fact, cardiac damage was even exaggerated by ischemic preconditioning in the absence of PKCδ [16] . This finding is in line with a recent clinical trial [40] , demonstrating that the intra-coronary application of high doses of a PKCδ inhibitor during primary percutaneous coronary intervention was associated with an increase, rather than a decrease, in infarct size [41] . Thus, deficiency for either PKCɛ or PKCδ is sufficient to abrogate the cardioprotective effects of ischemic preconditioning, indicating that an individual PKC isoform may not be cardioprotective per se, but that cardioprotection may require the interaction of both PKC isoforms and that the cardioprotective effect may be the consequence of their combined orchestration of cardiac glucose and energy metabolism (Fig. 8) .
Limitations of the study
Although proteomics and metabolomics offer a suite of tools to interrogate tissue metabolism [29, 37, 42] , it is important to acknowledge that both techniques are biased to high-abundant components. Moreover, metabolites were extracted directly from snap-frozen hearts and a reduction of a metabolite as measured by 1 H-NMR spectroscopy may be the consequence of increased consumption or decreased production. As enzymatic activity in tissues is reflected in the expression and post-translational modifications of enzymes [43] , 2-DE offers a particular advantage by visualizing posttranslational modifications of high abundant enzymes as a shift in isoelectric point or molecular weight [44] . In combination, these emerging technologies contribute to a better understanding of enzymatic and metabolite changes associated with PKCɛ-mediated cardioprotection.
Conclusion
While activation of PKCɛ and inhibition of PKCδ were known to be cardioprotective against ischemia/reperfusion injury, the common denominator in cardioprotective signalling between the two PKC isoforms remained unknown. Our studies demonstrate that PKCɛ and PKCδ influence key steps in glucose metabolism of murine hearts. Thus, these kinases appear to be uniquely positioned to integrate signalling with metabolism, a central determinant of cardiomyocyte life and death. Future studies will have to address whether a similar interplay between the two PKC isoforms is also observed in human hearts and other experimental models of cardioprotection. . Model for PKCɛ-initiated metabolic changes linked to cardioprotection. PKCɛ activation resulted in differential expression of pyruvate kinase (PK), enolase (Enol) and lactate dehydrogenase (LDH) with a corresponding reduction of glucose and lactate in murine hearts. Notably, a pronounced effect was also observed on cytosolic malate dehydrogenase (MDH) and aspartate aminotransferase (AAT), the two enzymatic components of the malate-aspartate shuttle. The latter transfers electrons from the cytoplasm to mitochondria and is important in allowing maximum release of the free energy in glycolysis under aerobic conditions. In contrast, inhibition of PKCɛ stimulated loop phosphorylation and translocation of PKCδ to cardiac mitochondria, where it targets the pyruvate dehydrogenase complex (PDC), the enzyme responsible for converting the glycolytic endproduct pyruvate to acetylCoA. The pyruvate dehydrogenase complex is located at the inner mitochondrial membrane and inhibited when phosphorylated by pyruvate dehydrogenase kinase (PDK) and activated upon dephosphorylation by pyruvate dehydrogenase phosphatase (PDP). Thus, PKCɛ and PKCδ activities influence key enzymatic reactions bridging aerobic and anaerobic glucose metabolism.
